DiStefano, as well as Kavita Nair, PhD, Joseph Saseen, PharmD, and Gina Moore, PharmD, will specifically study The Rise of Compounded GLP-1 Weight Loss Medications: A Landscape Analysis of the Direct-To-Consumer Market. Their study will look at the rise in compounded GLP-1 products, (so-called Ozempic knock-offs) advertised and sold to consumers by telehealth platforms, weight loss clinics, and medical spas
Descriptive statistics were utilized to summarize demographic information and clinical factor data
Safety and tolerability at higher doses appear acceptable based on preliminary data, but long-term experience is limited
When Insurance Says No: The Power of the Direct Path The most common outcome, unfortunately, is a denial
I started thinking there was a pattern there that needed to be looked at. Why These Episodes Can Be Dangerous Low blood pressure might sound less alarming than high blood pressure, but hypotensive episodes carry real risks, especially if they happen suddenly